$KRTL Holding Group, Inc. Announces Merger with In
Post# of 22
(Total Views: 70)
Posted On: 09/09/2025 10:45:09 AM
$KRTL Holding Group, Inc. Announces Merger with Industria Químico Farmacéutica Sigma Corp. S.R.L.
https://www.globenewswire.com/news-release/20...S-R-L.html
Lakewood, CO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group, Inc. (OTC: KRTL) (“KRTL Holding” or the “Company”) today announced that its wholly owned subsidiary, KRTL Biotech, Inc. (“KRTL Biotech”), has completed a merger by exchange of quotas and shares agreement with Industria Químico Farmacéutica Sigma Corp. S.R.L. (“SIGMA”), a leading Bolivian pharmaceutical manufacturer.
Under the terms of the Share and Quotas Exchange Agreement executed on September 2, 2025, the Wilstermann Family, owners of 100% of SIGMA, shall transfer 99% of SIGMA’s capital quotas to KRTL Biotech. In exchange, KRTL Holding, through KRTL Biotech, will issue 490,000,000 common shares of KRTL Biotech, representing 49% of KRTL Biotech’s issued and outstanding shares, to the Wilstermann Family.
Additionally, KRTL Holding will issue one (1) preferred share to Patricia Wilstermann, granting her a permanent board seat on KRTL Holding’s board, ensuring continuity of SIGMA’s governance interests.
This strategic transaction preserves SIGMA’s local operations, licenses, and management while granting KRTL Biotech a majority beneficial interest in SIGMA for financial consolidation under U.S. GAAP (ASC 810). SIGMA’s results will now be consolidated into KRTL Biotech’s financial statements, which are, in turn, consolidated into KRTL Holding’s reporting.
“This merger marks an important step forward in our expansion strategy,” said César Herrera, CEO of KRTL Holding Group, Inc. “By combining SIGMA’s established pharmaceutical operations in Bolivia with KRTL Biotech’s U.S. compliance framework, we are building a stronger, more integrated platform for growth.”
This merger creates a fully integrated commercial channel that strengthens the presence of both KRTL Biotech and SIGMA in the U.S. and Latin America. It enhances what the combined entity can manufacture in Bolivia and export into the United States while simultaneously creating new pathways for U.S.-based pharmaceutical innovation, technology, and therapeutics to be manufactured, distributed, and commercialized throughout Latin America. Through SIGMA’s local infrastructure, regulatory insight, and manufacturing capabilities, the alliance supports two-way pharmaceutical trade, compliance alignment, and scalable production on both sides of the hemisphere.
Dan Bishop, CEO of KRTL Biotech, Inc., added: “This unity aligns SIGMA’s proven manufacturing capabilities with KRTL Biotech’s regulatory and U.S. operational infrastructure. Together, we are positioned to better serve international markets while maintaining the highest quality standards.”
This collaboration not only enhances cross-border production and compliance but also sets a foundation for scientific innovation, bilateral trade expansion, and shared investment in public health. The merger enables each company to leverage its strengths—U.S.-based quality systems and regulatory insight, alongside Bolivian production depth and agility—to elevate pharmaceutical and nutraceutical development on a global scale.
Patricia Wilstermann, CEO of SIGMA, said: “We’re excited to join forces with KRTL while maintaining operational independence in Bolivia. This partnership strengthens our business and expands our reach without compromising our core values. Together, we are creating a platform that respects our legacy while propelling us into new markets with shared vision, scientific collaboration, and a firm commitment to regulatory excellence.”
Transaction Highlights
Structure: Merger via exchange of quotas and shares
Effective Date: September 2, 2025
Consideration:
99% of SIGMA’s capital quotas transferred to KRTL Biotech
490,000,000 common shares of KRTL Biotech issued to the Wilstermann Family (49% ownership)
One (1) preferred share issued to Patricia Wilstermann, who has also been granted a board seat at KRTL Holding
Consolidation: SIGMA’s financial results will be consolidated into KRTL Biotech’s statements under ASC 810
https://www.globenewswire.com/news-release/20...S-R-L.html
Lakewood, CO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group, Inc. (OTC: KRTL) (“KRTL Holding” or the “Company”) today announced that its wholly owned subsidiary, KRTL Biotech, Inc. (“KRTL Biotech”), has completed a merger by exchange of quotas and shares agreement with Industria Químico Farmacéutica Sigma Corp. S.R.L. (“SIGMA”), a leading Bolivian pharmaceutical manufacturer.
Under the terms of the Share and Quotas Exchange Agreement executed on September 2, 2025, the Wilstermann Family, owners of 100% of SIGMA, shall transfer 99% of SIGMA’s capital quotas to KRTL Biotech. In exchange, KRTL Holding, through KRTL Biotech, will issue 490,000,000 common shares of KRTL Biotech, representing 49% of KRTL Biotech’s issued and outstanding shares, to the Wilstermann Family.
Additionally, KRTL Holding will issue one (1) preferred share to Patricia Wilstermann, granting her a permanent board seat on KRTL Holding’s board, ensuring continuity of SIGMA’s governance interests.
This strategic transaction preserves SIGMA’s local operations, licenses, and management while granting KRTL Biotech a majority beneficial interest in SIGMA for financial consolidation under U.S. GAAP (ASC 810). SIGMA’s results will now be consolidated into KRTL Biotech’s financial statements, which are, in turn, consolidated into KRTL Holding’s reporting.
“This merger marks an important step forward in our expansion strategy,” said César Herrera, CEO of KRTL Holding Group, Inc. “By combining SIGMA’s established pharmaceutical operations in Bolivia with KRTL Biotech’s U.S. compliance framework, we are building a stronger, more integrated platform for growth.”
This merger creates a fully integrated commercial channel that strengthens the presence of both KRTL Biotech and SIGMA in the U.S. and Latin America. It enhances what the combined entity can manufacture in Bolivia and export into the United States while simultaneously creating new pathways for U.S.-based pharmaceutical innovation, technology, and therapeutics to be manufactured, distributed, and commercialized throughout Latin America. Through SIGMA’s local infrastructure, regulatory insight, and manufacturing capabilities, the alliance supports two-way pharmaceutical trade, compliance alignment, and scalable production on both sides of the hemisphere.
Dan Bishop, CEO of KRTL Biotech, Inc., added: “This unity aligns SIGMA’s proven manufacturing capabilities with KRTL Biotech’s regulatory and U.S. operational infrastructure. Together, we are positioned to better serve international markets while maintaining the highest quality standards.”
This collaboration not only enhances cross-border production and compliance but also sets a foundation for scientific innovation, bilateral trade expansion, and shared investment in public health. The merger enables each company to leverage its strengths—U.S.-based quality systems and regulatory insight, alongside Bolivian production depth and agility—to elevate pharmaceutical and nutraceutical development on a global scale.
Patricia Wilstermann, CEO of SIGMA, said: “We’re excited to join forces with KRTL while maintaining operational independence in Bolivia. This partnership strengthens our business and expands our reach without compromising our core values. Together, we are creating a platform that respects our legacy while propelling us into new markets with shared vision, scientific collaboration, and a firm commitment to regulatory excellence.”
Transaction Highlights
Structure: Merger via exchange of quotas and shares
Effective Date: September 2, 2025
Consideration:
99% of SIGMA’s capital quotas transferred to KRTL Biotech
490,000,000 common shares of KRTL Biotech issued to the Wilstermann Family (49% ownership)
One (1) preferred share issued to Patricia Wilstermann, who has also been granted a board seat at KRTL Holding
Consolidation: SIGMA’s financial results will be consolidated into KRTL Biotech’s statements under ASC 810
(0)
(0)